Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog

Background and Purpose:  Ziconotide is a peptide that blocks N‐type calcium channels and is antihyperalgesic after intrathecal (IT) delivery. We here characterize the spinal kinetics of IT bolus and infused ziconotide in dog. Experimental Approach:  Male beagle dogs (N= 5) were prepared with chronic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuromodulation (Malden, Mass.) Mass.), 2012-11, Vol.15 (6), p.508-519
Hauptverfasser: Yaksh, Tony L., de Kater, Annelies, Dean, Robin, Best, Brookie M., Miljanich, George P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 519
container_issue 6
container_start_page 508
container_title Neuromodulation (Malden, Mass.)
container_volume 15
creator Yaksh, Tony L.
de Kater, Annelies
Dean, Robin
Best, Brookie M.
Miljanich, George P.
description Background and Purpose:  Ziconotide is a peptide that blocks N‐type calcium channels and is antihyperalgesic after intrathecal (IT) delivery. We here characterize the spinal kinetics of IT bolus and infused ziconotide in dog. Experimental Approach:  Male beagle dogs (N= 5) were prepared with chronic IT lumbar injection and cerebrospinal fluid (LCSF) sampling catheters connected to vest‐mounted pumps. Each dog received the following: 1) IT bolus ziconotide (10 µg + 1 µCi 3H‐inulin); 2) IT infusion for 48 hours of ziconotide (1 µg/100 µL/hour); 3) IT infusion for 48 hours of ziconotide (5 µg/100 µL/hour); and 4) intravenous injection of ziconotide (0.1 mg/kg). After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T1/2‐α/β= 0.14 and 1.77 hours, and inulin T1/2‐α/β= 0.16 and 3.88 hours, respectively). The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours. IT infusion of 1 and then 5 µg/hour resulted in LCSF concentrations that peaked by eight hours and remained stable at 343 and 1380 ng/mL, respectively, to the end of the 48‐hour infusions. Terminal elimination T1/2 after termination of continuous infusion was 2.47 hours. Ziconotide LCSF : cisternal CSF : plasma concentration ratios after infusion of 1 and 5 µg/hour were 1:0.017:0.001 and 1:0.015:0.003, respectively. IT infusion of ziconotide at 1 µg/hour inhibited thermal skin twitch by 24 hours and produced modest trembling, ataxia, and decreased arousal. Effects continued through the 48‐hour infusion period, increased in magnitude during the subsequent 5 µg/hour infusion periods, and disappeared after drug clearance. Conclusions and Implications:  After IT bolus or infusion, ziconotide displays linear kinetics that are consistent with a hydrophilic molecule of approximately 2500 Da that is cleared slightly more rapidly than inulin from the LCSF. Behavioral effects were dose dependent and reversible.
doi_str_mv 10.1111/j.1525-1403.2012.00479.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3514653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1257772608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5979-3c7c323c23a1d6b69761acbd14ed0b322911f06599832db5b445a6825d59bcfb3</originalsourceid><addsrcrecordid>eNqNkd1u1DAQhSMEoqXwCsgSN0VqFv_EcSyhSm36Q1EVChQVcWM5jrPrrWMvcVJ2X4TnxdstK-AK33ikOecbj0-SAAQnKJ438wmimKYog2SCIcITCDPGJ8tHye628TjWkGcpQ5TvJM9CmEOIGMfsabKDMcsKBIvd5OfVTPadVP7WOD0YBY6ctKtgAvAt-GaUd34wjQb7n6uvaRz9-gBIBy7c0MthppW0oEqvVwsNSmmVGTtQzqRz2oJj61VkTu-BUx2MOgAn2po73esG1Ctw7O0YIqyJtHYMxjtgHIhQcOKnz5MnrbRBv3i495IvZ6fX5bv08sP5RXl0mSrKGU-JYopgojCRqMnrnLMcSVU3KNMNrAnGHKEW5pTzguCmpnWWUZkXmDaU16qtyV5yuOEuxrrTjdLrxaxY9KaT_Up4acTfHWdmYurvBKEoyymJgP0HQO-_jzoMojNBaWul034MAmHKGMM5LKL01T_SuR_7-DtRRbIccYIKFlXFRqV6H0Kv2-1jEBTr8MVcrDMW64zFOnxxH75YRuvLP5fZGn-nHQVvN4IfxurVf4NFdfopFtGebuwmDHq5tcv-VuSMMCpuqnPxMa_eX53hUtyQX6PFzEE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1346193187</pqid></control><display><type>article</type><title>Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Yaksh, Tony L. ; de Kater, Annelies ; Dean, Robin ; Best, Brookie M. ; Miljanich, George P.</creator><creatorcontrib>Yaksh, Tony L. ; de Kater, Annelies ; Dean, Robin ; Best, Brookie M. ; Miljanich, George P.</creatorcontrib><description>Background and Purpose:  Ziconotide is a peptide that blocks N‐type calcium channels and is antihyperalgesic after intrathecal (IT) delivery. We here characterize the spinal kinetics of IT bolus and infused ziconotide in dog. Experimental Approach:  Male beagle dogs (N= 5) were prepared with chronic IT lumbar injection and cerebrospinal fluid (LCSF) sampling catheters connected to vest‐mounted pumps. Each dog received the following: 1) IT bolus ziconotide (10 µg + 1 µCi 3H‐inulin); 2) IT infusion for 48 hours of ziconotide (1 µg/100 µL/hour); 3) IT infusion for 48 hours of ziconotide (5 µg/100 µL/hour); and 4) intravenous injection of ziconotide (0.1 mg/kg). After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T1/2‐α/β= 0.14 and 1.77 hours, and inulin T1/2‐α/β= 0.16 and 3.88 hours, respectively). The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours. IT infusion of 1 and then 5 µg/hour resulted in LCSF concentrations that peaked by eight hours and remained stable at 343 and 1380 ng/mL, respectively, to the end of the 48‐hour infusions. Terminal elimination T1/2 after termination of continuous infusion was 2.47 hours. Ziconotide LCSF : cisternal CSF : plasma concentration ratios after infusion of 1 and 5 µg/hour were 1:0.017:0.001 and 1:0.015:0.003, respectively. IT infusion of ziconotide at 1 µg/hour inhibited thermal skin twitch by 24 hours and produced modest trembling, ataxia, and decreased arousal. Effects continued through the 48‐hour infusion period, increased in magnitude during the subsequent 5 µg/hour infusion periods, and disappeared after drug clearance. Conclusions and Implications:  After IT bolus or infusion, ziconotide displays linear kinetics that are consistent with a hydrophilic molecule of approximately 2500 Da that is cleared slightly more rapidly than inulin from the LCSF. Behavioral effects were dose dependent and reversible.</description><identifier>ISSN: 1094-7159</identifier><identifier>EISSN: 1525-1403</identifier><identifier>DOI: 10.1111/j.1525-1403.2012.00479.x</identifier><identifier>PMID: 22748108</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Analgesia ; Animals ; antinociception ; Area Under Curve ; Arousal - drug effects ; blood pressure ; Blood Pressure - drug effects ; Calcium Channel Blockers - administration &amp; dosage ; Calcium Channel Blockers - blood ; Calcium Channel Blockers - cerebrospinal fluid ; Calcium Channel Blockers - pharmacokinetics ; Dogs ; Dose-Response Relationship, Drug ; Heart Rate - drug effects ; Infusions, Parenteral - methods ; Injections, Spinal - methods ; intrathecal ; kinetics ; Male ; Motor Activity - drug effects ; Nociception - drug effects ; omega-Conotoxins - administration &amp; dosage ; omega-Conotoxins - blood ; omega-Conotoxins - cerebrospinal fluid ; omega-Conotoxins - pharmacokinetics ; Pharmacokinetics ; PRIALT ; Skin - innervation ; SNX-111 ; spinal ; Time Factors ; ziconotide</subject><ispartof>Neuromodulation (Malden, Mass.), 2012-11, Vol.15 (6), p.508-519</ispartof><rights>2012 International Neuromodulation Society</rights><rights>2012 International Neuromodulation Society.</rights><rights>Copyright 2012 International Neuromodulation Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5979-3c7c323c23a1d6b69761acbd14ed0b322911f06599832db5b445a6825d59bcfb3</citedby><cites>FETCH-LOGICAL-c5979-3c7c323c23a1d6b69761acbd14ed0b322911f06599832db5b445a6825d59bcfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22748108$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yaksh, Tony L.</creatorcontrib><creatorcontrib>de Kater, Annelies</creatorcontrib><creatorcontrib>Dean, Robin</creatorcontrib><creatorcontrib>Best, Brookie M.</creatorcontrib><creatorcontrib>Miljanich, George P.</creatorcontrib><title>Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog</title><title>Neuromodulation (Malden, Mass.)</title><addtitle>Neuromodulation</addtitle><description>Background and Purpose:  Ziconotide is a peptide that blocks N‐type calcium channels and is antihyperalgesic after intrathecal (IT) delivery. We here characterize the spinal kinetics of IT bolus and infused ziconotide in dog. Experimental Approach:  Male beagle dogs (N= 5) were prepared with chronic IT lumbar injection and cerebrospinal fluid (LCSF) sampling catheters connected to vest‐mounted pumps. Each dog received the following: 1) IT bolus ziconotide (10 µg + 1 µCi 3H‐inulin); 2) IT infusion for 48 hours of ziconotide (1 µg/100 µL/hour); 3) IT infusion for 48 hours of ziconotide (5 µg/100 µL/hour); and 4) intravenous injection of ziconotide (0.1 mg/kg). After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T1/2‐α/β= 0.14 and 1.77 hours, and inulin T1/2‐α/β= 0.16 and 3.88 hours, respectively). The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours. IT infusion of 1 and then 5 µg/hour resulted in LCSF concentrations that peaked by eight hours and remained stable at 343 and 1380 ng/mL, respectively, to the end of the 48‐hour infusions. Terminal elimination T1/2 after termination of continuous infusion was 2.47 hours. Ziconotide LCSF : cisternal CSF : plasma concentration ratios after infusion of 1 and 5 µg/hour were 1:0.017:0.001 and 1:0.015:0.003, respectively. IT infusion of ziconotide at 1 µg/hour inhibited thermal skin twitch by 24 hours and produced modest trembling, ataxia, and decreased arousal. Effects continued through the 48‐hour infusion period, increased in magnitude during the subsequent 5 µg/hour infusion periods, and disappeared after drug clearance. Conclusions and Implications:  After IT bolus or infusion, ziconotide displays linear kinetics that are consistent with a hydrophilic molecule of approximately 2500 Da that is cleared slightly more rapidly than inulin from the LCSF. Behavioral effects were dose dependent and reversible.</description><subject>Analgesia</subject><subject>Animals</subject><subject>antinociception</subject><subject>Area Under Curve</subject><subject>Arousal - drug effects</subject><subject>blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - administration &amp; dosage</subject><subject>Calcium Channel Blockers - blood</subject><subject>Calcium Channel Blockers - cerebrospinal fluid</subject><subject>Calcium Channel Blockers - pharmacokinetics</subject><subject>Dogs</subject><subject>Dose-Response Relationship, Drug</subject><subject>Heart Rate - drug effects</subject><subject>Infusions, Parenteral - methods</subject><subject>Injections, Spinal - methods</subject><subject>intrathecal</subject><subject>kinetics</subject><subject>Male</subject><subject>Motor Activity - drug effects</subject><subject>Nociception - drug effects</subject><subject>omega-Conotoxins - administration &amp; dosage</subject><subject>omega-Conotoxins - blood</subject><subject>omega-Conotoxins - cerebrospinal fluid</subject><subject>omega-Conotoxins - pharmacokinetics</subject><subject>Pharmacokinetics</subject><subject>PRIALT</subject><subject>Skin - innervation</subject><subject>SNX-111</subject><subject>spinal</subject><subject>Time Factors</subject><subject>ziconotide</subject><issn>1094-7159</issn><issn>1525-1403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd1u1DAQhSMEoqXwCsgSN0VqFv_EcSyhSm36Q1EVChQVcWM5jrPrrWMvcVJ2X4TnxdstK-AK33ikOecbj0-SAAQnKJ438wmimKYog2SCIcITCDPGJ8tHye628TjWkGcpQ5TvJM9CmEOIGMfsabKDMcsKBIvd5OfVTPadVP7WOD0YBY6ctKtgAvAt-GaUd34wjQb7n6uvaRz9-gBIBy7c0MthppW0oEqvVwsNSmmVGTtQzqRz2oJj61VkTu-BUx2MOgAn2po73esG1Ctw7O0YIqyJtHYMxjtgHIhQcOKnz5MnrbRBv3i495IvZ6fX5bv08sP5RXl0mSrKGU-JYopgojCRqMnrnLMcSVU3KNMNrAnGHKEW5pTzguCmpnWWUZkXmDaU16qtyV5yuOEuxrrTjdLrxaxY9KaT_Up4acTfHWdmYurvBKEoyymJgP0HQO-_jzoMojNBaWul034MAmHKGMM5LKL01T_SuR_7-DtRRbIccYIKFlXFRqV6H0Kv2-1jEBTr8MVcrDMW64zFOnxxH75YRuvLP5fZGn-nHQVvN4IfxurVf4NFdfopFtGebuwmDHq5tcv-VuSMMCpuqnPxMa_eX53hUtyQX6PFzEE</recordid><startdate>201211</startdate><enddate>201211</enddate><creator>Yaksh, Tony L.</creator><creator>de Kater, Annelies</creator><creator>Dean, Robin</creator><creator>Best, Brookie M.</creator><creator>Miljanich, George P.</creator><general>Blackwell Publishing Inc</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7TN</scope><scope>F1W</scope><scope>H95</scope><scope>L.G</scope><scope>5PM</scope></search><sort><creationdate>201211</creationdate><title>Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog</title><author>Yaksh, Tony L. ; de Kater, Annelies ; Dean, Robin ; Best, Brookie M. ; Miljanich, George P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5979-3c7c323c23a1d6b69761acbd14ed0b322911f06599832db5b445a6825d59bcfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Analgesia</topic><topic>Animals</topic><topic>antinociception</topic><topic>Area Under Curve</topic><topic>Arousal - drug effects</topic><topic>blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - administration &amp; dosage</topic><topic>Calcium Channel Blockers - blood</topic><topic>Calcium Channel Blockers - cerebrospinal fluid</topic><topic>Calcium Channel Blockers - pharmacokinetics</topic><topic>Dogs</topic><topic>Dose-Response Relationship, Drug</topic><topic>Heart Rate - drug effects</topic><topic>Infusions, Parenteral - methods</topic><topic>Injections, Spinal - methods</topic><topic>intrathecal</topic><topic>kinetics</topic><topic>Male</topic><topic>Motor Activity - drug effects</topic><topic>Nociception - drug effects</topic><topic>omega-Conotoxins - administration &amp; dosage</topic><topic>omega-Conotoxins - blood</topic><topic>omega-Conotoxins - cerebrospinal fluid</topic><topic>omega-Conotoxins - pharmacokinetics</topic><topic>Pharmacokinetics</topic><topic>PRIALT</topic><topic>Skin - innervation</topic><topic>SNX-111</topic><topic>spinal</topic><topic>Time Factors</topic><topic>ziconotide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yaksh, Tony L.</creatorcontrib><creatorcontrib>de Kater, Annelies</creatorcontrib><creatorcontrib>Dean, Robin</creatorcontrib><creatorcontrib>Best, Brookie M.</creatorcontrib><creatorcontrib>Miljanich, George P.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Oceanic Abstracts</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuromodulation (Malden, Mass.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yaksh, Tony L.</au><au>de Kater, Annelies</au><au>Dean, Robin</au><au>Best, Brookie M.</au><au>Miljanich, George P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog</atitle><jtitle>Neuromodulation (Malden, Mass.)</jtitle><addtitle>Neuromodulation</addtitle><date>2012-11</date><risdate>2012</risdate><volume>15</volume><issue>6</issue><spage>508</spage><epage>519</epage><pages>508-519</pages><issn>1094-7159</issn><eissn>1525-1403</eissn><abstract>Background and Purpose:  Ziconotide is a peptide that blocks N‐type calcium channels and is antihyperalgesic after intrathecal (IT) delivery. We here characterize the spinal kinetics of IT bolus and infused ziconotide in dog. Experimental Approach:  Male beagle dogs (N= 5) were prepared with chronic IT lumbar injection and cerebrospinal fluid (LCSF) sampling catheters connected to vest‐mounted pumps. Each dog received the following: 1) IT bolus ziconotide (10 µg + 1 µCi 3H‐inulin); 2) IT infusion for 48 hours of ziconotide (1 µg/100 µL/hour); 3) IT infusion for 48 hours of ziconotide (5 µg/100 µL/hour); and 4) intravenous injection of ziconotide (0.1 mg/kg). After IT bolus, LCSF ziconotide and inulin showed an initial peak and biphasic (distribution/elimination) clearance (ziconotide T1/2‐α/β= 0.14 and 1.77 hours, and inulin T1/2‐α/β= 0.16 and 3.88 hours, respectively). The LCSF : plasma ziconotide concentration ratio was 20,000:1 at 30 min and 30:1 at eight hours. IT infusion of 1 and then 5 µg/hour resulted in LCSF concentrations that peaked by eight hours and remained stable at 343 and 1380 ng/mL, respectively, to the end of the 48‐hour infusions. Terminal elimination T1/2 after termination of continuous infusion was 2.47 hours. Ziconotide LCSF : cisternal CSF : plasma concentration ratios after infusion of 1 and 5 µg/hour were 1:0.017:0.001 and 1:0.015:0.003, respectively. IT infusion of ziconotide at 1 µg/hour inhibited thermal skin twitch by 24 hours and produced modest trembling, ataxia, and decreased arousal. Effects continued through the 48‐hour infusion period, increased in magnitude during the subsequent 5 µg/hour infusion periods, and disappeared after drug clearance. Conclusions and Implications:  After IT bolus or infusion, ziconotide displays linear kinetics that are consistent with a hydrophilic molecule of approximately 2500 Da that is cleared slightly more rapidly than inulin from the LCSF. Behavioral effects were dose dependent and reversible.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>22748108</pmid><doi>10.1111/j.1525-1403.2012.00479.x</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1094-7159
ispartof Neuromodulation (Malden, Mass.), 2012-11, Vol.15 (6), p.508-519
issn 1094-7159
1525-1403
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3514653
source MEDLINE; Alma/SFX Local Collection
subjects Analgesia
Animals
antinociception
Area Under Curve
Arousal - drug effects
blood pressure
Blood Pressure - drug effects
Calcium Channel Blockers - administration & dosage
Calcium Channel Blockers - blood
Calcium Channel Blockers - cerebrospinal fluid
Calcium Channel Blockers - pharmacokinetics
Dogs
Dose-Response Relationship, Drug
Heart Rate - drug effects
Infusions, Parenteral - methods
Injections, Spinal - methods
intrathecal
kinetics
Male
Motor Activity - drug effects
Nociception - drug effects
omega-Conotoxins - administration & dosage
omega-Conotoxins - blood
omega-Conotoxins - cerebrospinal fluid
omega-Conotoxins - pharmacokinetics
Pharmacokinetics
PRIALT
Skin - innervation
SNX-111
spinal
Time Factors
ziconotide
title Pharmacokinetic Analysis of Ziconotide (SNX-111), an Intrathecal N-Type Calcium Channel Blocking Analgesic, Delivered by Bolus and Infusion in the Dog
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T02%3A28%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20Analysis%20of%20Ziconotide%20(SNX-111),%20an%20Intrathecal%20N-Type%20Calcium%20Channel%20Blocking%20Analgesic,%20Delivered%20by%20Bolus%20and%20Infusion%20in%20the%20Dog&rft.jtitle=Neuromodulation%20(Malden,%20Mass.)&rft.au=Yaksh,%20Tony%20L.&rft.date=2012-11&rft.volume=15&rft.issue=6&rft.spage=508&rft.epage=519&rft.pages=508-519&rft.issn=1094-7159&rft.eissn=1525-1403&rft_id=info:doi/10.1111/j.1525-1403.2012.00479.x&rft_dat=%3Cproquest_pubme%3E1257772608%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1346193187&rft_id=info:pmid/22748108&rfr_iscdi=true